127 related articles for article (PubMed ID: 2244933)
1. Effect of thromboxane synthetase inhibition and angiotensin converting enzyme inhibition on acute cyclosporin A nephrotoxicity.
Grieve EM; Hawksworth GM; Simpson JG; Whiting PH
Biochem Pharmacol; 1990 Nov; 40(10):2323-9. PubMed ID: 2244933
[TBL] [Abstract][Full Text] [Related]
2. The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition.
Grieve EM; Hawksworth GM; Simpson JG; Whiting PH
Biochem Pharmacol; 1993 Mar; 45(6):1351-4. PubMed ID: 8466554
[TBL] [Abstract][Full Text] [Related]
3. Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity.
Benigni A; Chiabrando C; Piccinelli A; Perico N; Gavinelli M; Furci L; Patino O; Abbate M; Bertani T; Remuzzi G
Kidney Int; 1988 Aug; 34(2):164-74. PubMed ID: 3184595
[TBL] [Abstract][Full Text] [Related]
4. Modulation of experimental cyclosporine nephrotoxicity by inhibition of thromboxane synthesis.
Petric R; Freeman D; Wallace C; McDonald J; Stiller C; Keown P
Transplantation; 1990 Oct; 50(4):558-63. PubMed ID: 2219273
[TBL] [Abstract][Full Text] [Related]
5. The relationship of urinary thromboxane excretion to cyclosporine nephrotoxicity.
Schnabel FR; Wait RB; Kahng KU
Transplantation; 1991 Mar; 51(3):686-9. PubMed ID: 2006526
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of thromboxane synthetase potentiates the antihypertensive action of an angiotensin-converting enzyme inhibitor by a prostaglandin-dependent but kinin-independent mechanism.
Levens NR; Cóte D; Ksander G
J Pharmacol Exp Ther; 1991 Oct; 259(1):219-27. PubMed ID: 1920118
[TBL] [Abstract][Full Text] [Related]
7. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity.
Smith SR; Kubacki VB; Rakhit A; Martin LL; Schaffer AV; Jasani MK; Hefty DJ; Johnston T; Cannon C; Bennett WM
Transplantation; 1993 Dec; 56(6):1422-6. PubMed ID: 8279014
[TBL] [Abstract][Full Text] [Related]
8. Reduction of chronic ciclosporin nephrotoxicity by thromboxane synthase inhibition with OKY-046.
Kim YJ; Park YH; Moon HK
Kidney Blood Press Res; 1997; 20(1):38-43. PubMed ID: 9192909
[TBL] [Abstract][Full Text] [Related]
9. The protective effects of the thromboxane synthetase inhibitor Dazmegrel on nephrotoxicity in cyclosporine-treated rats.
Gladue RP; Newborg MF
Transplantation; 1991 Nov; 52(5):837-41. PubMed ID: 1949170
[TBL] [Abstract][Full Text] [Related]
10. Alleviation of experimental cyclosporin A toxicity by substitution of fish muscle oil as drug vehicle.
Craighead IB; Heys SD; Smart LM; Thomson AW; Whiting PH
Immunopharmacology; 1990; 20(1):21-9. PubMed ID: 2228568
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporin A-induced nephrotoxicity in the rat: relationship to increased plasma renin activity.
McAuley FT; Simpson JG; Thomson AW; Whiting PH
Agents Actions; 1987 Jun; 21(1-2):209-16. PubMed ID: 3307341
[TBL] [Abstract][Full Text] [Related]
12. Effects of dietary n-3 fatty acid supplementation versus thromboxane synthetase inhibition on gentamicin-induced nephrotoxicosis in healthy male dogs.
Grauer GF; Greco DS; Behrend EN; Fettman MJ; Mani I; Getzy DM; Reinhart GA
Am J Vet Res; 1996 Jun; 57(6):948-56. PubMed ID: 8725828
[TBL] [Abstract][Full Text] [Related]
13. The influence of enalapril or spironolactone on experimental cyclosporin nephrotoxicity.
McAuley FT; Whiting PH; Thomson AW; Simpson JG
Biochem Pharmacol; 1987 Mar; 36(5):699-703. PubMed ID: 3030332
[TBL] [Abstract][Full Text] [Related]
14. The role of eicosanoids in cyclosporine nephrotoxicity in the rat.
Erman A; Chen-Gal B; Rosenfeld J
Biochem Pharmacol; 1989 Jul; 38(13):2153-7. PubMed ID: 2735953
[TBL] [Abstract][Full Text] [Related]
15. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity.
Coffman TM; Carr DR; Yarger WE; Klotman PE
Transplantation; 1987 Feb; 43(2):282-5. PubMed ID: 3810836
[TBL] [Abstract][Full Text] [Related]
16. Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A.
Burdmann EA; Andoh TF; Rosen S; Lindsley J; Munar MY; Elzinga LW; Bennett WM
Kidney Int; 1994 Mar; 45(3):684-91. PubMed ID: 8196271
[TBL] [Abstract][Full Text] [Related]
17. Chronic cyclosporin A (CsA) nephrotoxicity in the rat: the effect of calcium blockade with verapamil.
Shaikh MG; Heys SD; Brown PA; Whiting PH
Int J Exp Pathol; 1993 Aug; 74(4):389-96. PubMed ID: 8398812
[TBL] [Abstract][Full Text] [Related]
18. Thromboxane synthase inhibition enhances action of converting enzyme inhibitors.
Levens NR; Ksander GM; Zimmerman MB; Mullane KM
Hypertension; 1989 Jan; 13(1):51-62. PubMed ID: 2910814
[TBL] [Abstract][Full Text] [Related]
19. Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor.
Smeesters C; Chaland P; Giroux L; Moutquin JM; Etienne P; Douglas F; Corman J; St-Louis G; Daloze P
Transplant Proc; 1988 Apr; 20(2 Suppl 2):663-9. PubMed ID: 3163209
[No Abstract] [Full Text] [Related]
20. Absence of acute nephrotoxicity with low doses of cyclosporin: experimental study in the rat.
Sabbatini M; De Nicola L; Uccello F; Russo D; Conte G; Dal Canton A; Andreucci VE
Nephrol Dial Transplant; 1990; 5(1):69-74. PubMed ID: 2109287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
